Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Hyun-Jae | - |
dc.contributor.author | Oh, Il-Young | - |
dc.contributor.author | Chung, Jin-Wook | - |
dc.contributor.author | Yang, Han-Mo | - |
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Park, Kyung Woo | - |
dc.contributor.author | Kwon, Taek Keun | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Cho, Young-Seok | - |
dc.contributor.author | Youn, Tae-Jin | - |
dc.contributor.author | Koo, Bon-Kwon | - |
dc.contributor.author | Kang, Won-Yu | - |
dc.contributor.author | Kim, Weon | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Bae, Jang Ho | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-09-06T14:07:01Z | - |
dc.date.available | 2021-09-06T14:07:01Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2012-11 | - |
dc.identifier.issn | 0195-668X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/107166 | - |
dc.description.abstract | Aims In the previous COREA-TAXUS trial, a 6-month adjunctive use of celecoxib reduced target-lesion revascularization (TLR) without increased thrombotic risk. We aimed to confirm the effects of 3-month celecoxib in patients receiving drug-eluting stent (DES) implantation in the larger prospective, randomized trial. Methods and results Patients (n = 909) treated for native coronary lesions were randomized into four groups: the control or the celecoxib group with stratification by stents: paclitaxel-eluting stent (PES) or zotarolimus-eluting stent (ZES). In the celecoxib group, 200 mg of celecoxib was given twice daily for 3 months after the procedure. The primary endpoint was in-stent late loss (LL) at 6 months. In-stent LL was significantly lower in the celecoxib group than the control group (0.64 +/- 0.54 vs. 0.55 +/- 0.47 mm, P = 0.02). The trend of LL reduction in the celecoxib group was maintained in the ZES and PES subgroups, although it did not reach statistical significance. There was a trend towards the reduced clinically driven TLR in the celecoxib group (5.7 vs. 3.2, log-rank P = 0.09), but adverse cardiac events rate did not differ between the two groups (composite of cardiac death, non-fatal myocardial infarction, and TLR; 8.6 vs. 7.7, log-rank P = 0.84). Non-fatal myocardial infarction and cardiac death occurred in 1.6 of the patients in the celecoxib group when compared with 0.2 in the control group (log-rank P = 0.03). Conclusion Three-month adjunctive celecoxib would be useful to reduce LL of DES. However, this study may raise the concern about increased thrombotic risk with celecoxib even in patients receiving dual anti-platelet therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject | ELUTING STENT IMPLANTATION | - |
dc.subject | DUAL ANTIPLATELET THERAPY | - |
dc.subject | CYCLOOXYGENASE-2 INHIBITOR | - |
dc.subject | CARDIOVASCULAR RISK | - |
dc.subject | TAXUS TRIAL | - |
dc.subject | LESIONS | - |
dc.subject | ARTERY | - |
dc.subject | CELLS | - |
dc.subject | PREVENTION | - |
dc.subject | APOPTOSIS | - |
dc.title | Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1093/eurheartj/ehs001 | - |
dc.identifier.scopusid | 2-s2.0-84868573383 | - |
dc.identifier.wosid | 000310628700013 | - |
dc.identifier.bibliographicCitation | EUROPEAN HEART JOURNAL, v.33, no.21, pp.2653 - 2661 | - |
dc.relation.isPartOf | EUROPEAN HEART JOURNAL | - |
dc.citation.title | EUROPEAN HEART JOURNAL | - |
dc.citation.volume | 33 | - |
dc.citation.number | 21 | - |
dc.citation.startPage | 2653 | - |
dc.citation.endPage | 2661 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ELUTING STENT IMPLANTATION | - |
dc.subject.keywordPlus | DUAL ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | CYCLOOXYGENASE-2 INHIBITOR | - |
dc.subject.keywordPlus | CARDIOVASCULAR RISK | - |
dc.subject.keywordPlus | TAXUS TRIAL | - |
dc.subject.keywordPlus | LESIONS | - |
dc.subject.keywordPlus | ARTERY | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordAuthor | Celecoxib | - |
dc.subject.keywordAuthor | Drug-eluting stent | - |
dc.subject.keywordAuthor | Stent thrombosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.